JDRF funding opportunities

We offer a wide range of funding schemes for qualified researchers in the field of type 1 diabetes and its associated complications.

The following JDRF funding opportunities are administered by our central office in New York. Applications must be submitted via RMS360, the JDRF Grant Management System. This page provides applicants with guidelines for application submission.

Please follow the links below to find out more about these opportunities.

Open calls

Cures

Development of Islet-Targeted Drug Delivery Strategies in T1D
The goal of this funding opportunity is the creation and validation of reagents that convey islet cell type specificity for the purposes of targeted drug delivery.
Respondents to this RFA should have demonstrated expertise in the development and validation of drug delivery platforms; the discovery and validation of new cellular addresses/reagents with
characteristics appropriate for active drug delivery to human islet endocrine cells; and/or the ability to deliver a model payload into a human islet cell, both in vitro and in vivo.
This program will award grants of up to $900k over 3 years.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 17 August 2022.

Notification of Full Application Request: 2 September 2022.
Full Application Deadline (on invite only): 5 October 2022.
Response to Applicants: 31 March 2023.
Earliest anticipated start date: 31 May 2023.

Realignment of Established Targets and Mechanisms for Delaying or Reversing T1D
The goal of this funding opportunity is to identity new candidates for clinical intervention in T1D by identifying and validating targets and mechanisms from other disease indications or disciplines, and welcome new perspectives, approaches, and investigators into the search for a cure for T1D.
Proposals eligible for consideration will describe studies that accelerate T1D research by realigning targets and mechanisms established in other diseases/focuses that have not
previously been interrogated for a role in the mechanisms driving disease in stages 1-3 of T1D.
This program will award grants of up to $750,000.00 over 3 years.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 23 August 2022.

Notification of Full Application Request: 7 September 2022.
Full Application Deadline (on invite only): 4 October 2022.
Response to Applicants: 28 February 2023.
Earliest anticipated start date: 30 April 2023.

Development and Validation of NonInvasive Immune Imaging Technology to Accelerate the Development of Beta Cell Replacement Therapies
The goal of this funding opportunity is to catalyze the development and in vivo validation of medical imaging and theranostic technology that enables the non-invasive in vivo monitoring and modulation of immune responses towards transplanted insulin-producing cells.
Proposals eligible for consideration will describe studies on the development of novel probes and tracers that enhance imaging specificity and sensitivity and enable multimodal and/or multiplexed imaging of immune system components of interest, and validation of such probes in in vivo models of islet transplantation. Multi-disciplinary collaborative projects are strongly encouraged and will be prioritized.
This program will award grants of up to $750,000 over 3 years. Larger/longer awards may be considered following discussion with the JDRF scientific lead.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 30 August 2022.

Notification of Full Application Request: 14 September 2022.
Full Application Deadline (on invite only): 12 October 2022.
Response to Applicants: 30 April 2023.
Earliest anticipated start date: 30 June 2023.

Targeted schemes

Cures

Development and Validation of NonInvasive Immune Imaging Technology to Accelerate the Development of Beta Cell Replacement Therapies
The goal of this funding opportunity is to catalyze the development and in vivo validation of medical imaging and theranostic technology that enables the non-invasive in vivo monitoring and modulation of immune responses towards transplanted insulin-producing cells.
Proposals eligible for consideration will describe studies on the development of novel probes and tracers that enhance imaging specificity and sensitivity and enable multimodal and/or multiplexed imaging of immune system components of interest, and validation of such probes in in vivo models of islet transplantation. Multi-disciplinary collaborative projects are strongly encouraged and will be prioritized.
This program will award grants of up to $750,000 over 3 years. Larger/longer awards may be considered following discussion with the JDRF scientific lead.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 30 August 2022.

Notification of Full Application Request: 14 September 2022.
Full Application Deadline (on invite only): 12 October 2022.
Response to Applicants: 30 April 2023.
Earliest anticipated start date: 30 June 2023.

Realignment of Established Targets and Mechanisms for Delaying or Reversing T1D
The goal of this funding opportunity is to identity new candidates for clinical intervention in T1D by identifying and validating targets and mechanisms from other disease indications or disciplines, and welcome new perspectives, approaches, and investigators into the search for a cure for T1D.
Proposals eligible for consideration will describe studies that accelerate T1D research by realigning targets and mechanisms established in other diseases/focuses that have not
previously been interrogated for a role in the mechanisms driving disease in stages 1-3 of T1D.
This program will award grants of up to $750,000.00 over 3 years
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 23 August 2022.

Notification of Full Application Request: 7 September 2022.
Full Application Deadline (on invite only): 4 October 2022.
Response to Applicants: 28 February 2023.
Earliest anticipated start date: 30 April 2023.

Development of Islet-Targeted Drug Delivery Strategies in T1D
The goal of this funding opportunity is the creation and validation of reagents that convey islet cell type specificity for the purposes of targeted drug delivery.
Respondents to this RFA should have demonstrated expertise in the development and validation of drug delivery platforms; the discovery and validation of new cellular addresses/reagents with
characteristics appropriate for active drug delivery to human islet endocrine cells; and/or the ability to deliver a model payload into a human islet cell, both in vitro and in vivo.
This program will award grants of up to $900k over 3 years.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 17 August 2022.

Notification of Full Application Request: 2 September 2022.
Full Application Deadline (on invite only): 5 October 2022.
Response to Applicants: 31 March 2023.
Earliest anticipated start date: 31 May 2023.

 Improving Risk Prediction for T1D Onset: Modelling and Assay Development for Clinical and Commercial Use
Letter of Intent Deadline: 15 December 2021.
Full Application Deadline (on invite only): 16 February 2022.
Response to Applicants: 30 June 2022.
Earliest anticipated start date: 31 August 2022.

Novel Immune Strategies to Enhance Beta Cell Replacement Therapies for T1D
Letter of Intent Deadline was 25 October 2021.
Full Application Deadline (on invite only): 20 December 2021.
Response to Applicants: 30 April 2022.
Earliest anticipated start date: 31 July 2022.

Developing Combination Therapies in Type 1 Diabetes
Letter of Intent Deadline was 17 November 2021.
Full Application Deadline (on invite only): 31 January 2022.
Response to Applicants: 31 May 2022.
Earliest anticipated start date: 31 July 2022.

Improving Lives
Clinical Trials and Mechanistic Clinical Studies to Advance Adjunctive Therapies for Glucometabolic Control in Type 1 Diabetes
Insulin is required for all people with T1D. However, for most people, insulin monotherapy is insufficient for optimal glucose control. Adjunctive therapies must be developed to address both glucose and broader metabolic control. This RFA is intended to support (1) clinical trials testing therapies—novel or repositioned, approved or in clinical development— for glucometabolic control in T1D, or (2) mechanistic clinical research to inform a better understanding of T1D glucometabolic imbalances to enable future therapy development.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline was 21 June 2022.
Notification of Full Application Request: 12 July 2022.
Full Application Deadline (on invite only): 23 August 2022.
Response to Applicants: 28 February 2023.
Earliest anticipated start date: 1 April 2023.

User-centric Insulin Pumps
AP systems also have the potential to improve quality of life by reducing the burden of disease management; however, for many this benefit is stymied by the on-body burden of wearing an insulin pump, which results in some people with T1D choosing not to take advantage of AP system technology despite the proven clinical benefits. This RFA is intended to solicit projects to develop “user-centric” pumps that impose less physical and psychological burden on people with T1D as well as people with type 2 diabetes who use insulin, so as to enable greater adoption of pumps and AP systems.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline is 10 May 2022.
Notification of Full Application Request: 31 May 2022.
Full Application Deadline (on invite only): 13 July 2022.
Response to Applicants: 28 February 2023.
Earliest anticipated start date: 1 April 2023.

– Clinical Trials to Advance Therapies for Nephropathy and Cardiovascular Disease in Type 1 Diabetes
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline was 8 November 2021.
Full Application Deadline (on invite only): 5 January 2022.
Response to Applicants: 31 May 2022.
Earliest anticipated start date: 31 August 2022.

Novel Approaches to Address Disordered Eating and Eating Disorders in Type 1 Diabetes
Letter of Intent Deadline was 27 October 2021.
Full Application Deadline (on invite only): 6 December 2021.
Response to Applicants: 30 April 2022.
Earliest anticipated start date: 30 June 2022.

Training funding schemes

These funding sources are typically available annually

Postdoctoral Fellowships
– Open to those at a relatively early stage of their career.
– PhD, MD, DMD, DVM, or equivalent received no more than five years before the application is submitted. Must not be simultaneously serving an internship or residency.
– Up to  $57,984 to $69,060 per year, for up to 3 years
– The application deadline was Wednesday 29 June 2022.
– Funding notification: 31 January 2023.
– Earliest start: 1 March 2023.
Note: In line with other JDRF fellowships, applicants may be eligible for a JDRF UK Postdoctoral Fellowship Research Communication Stipend.

Advanced Postdoctoral Fellowships
– Open to those who have completed some postdoctoral training, show extraordinary promise and are preparing for a transition to an independent research position.
– PhD, MD, DMD, DVM, or equivalent received no more than six years before the application is submitted. Must not be simultaneously serving an internship or residency.
– Up to $95,000 per year, for up to 3 years.
– The application deadline was Wednesday 29 June 2022.
– Funding notification: 31 January 2023.
– Earliest start: 1 March 2023.

Career Development Awards
– Open to individuals at an early stage of their independent academic career.
– PhD, MD, DMD, DVM, or equivalent and in an academic faculty-level position since less than 3 years before the submission date.
– Up to $150,000 per year, for up to 5 years.
– The application deadline was Wednesday 29 June 2022.
– Funding notification: 31 January 2023.
– Earliest start: 1 March 2023.

Early Career Patient-Orientated Diabetes Research Awards
– Open to clinical researchers at a relatively early stage of their independent career.
– MD or MR-PhD and in their first faculty-level appointment less than 5 years before the submission date.
– Up to $150,000 per year, for up to 5 years.
– The application deadline was Wednesday 29 June 2022.
– Funding notification: 31 January 2023.
– Earliest start: 1 March 2023.

JDRF International Diabetes Psychology Fellowship Program
– The fellowship is intended for those at a relatively early stage of their career.
– PhD, PsyD, DClinPsy, MD or equivalent from an accredited institution gained no more than 5 years prior application submission
– Not be simultaneously serving an internship or residency.
– Up to $65,000 per year, for up to 2 years.
– The application deadline was Tuesday 9 November 2021.
– Funding notification: 21 February 2022.
– Earliest start: 1 April 2022.
Note: In line with other JDRF fellowships, applicants may be eligible for a JDRF UK Postdoctoral Fellowship Research Communication Stipend.

Ongoing funding schemes

Project Concepts for Strategic Research Agreements
– Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research.
– PhD, MD, DMD, DVM, or equivalent and in a faculty position or equivalent.
Project concept Letter of Intent deadlines are Wednesday 2 November 2022 and Wednesday 3 May 2023.
– Successful Project Concept applicants will be contacted by JDRF staff for further project development by 16 December 2022 and 16 June 2023.

Innovative Grants
– Funding for highly innovative research proposals with significant potential to accelerate JDRF’s mission.
– PhD, MD, DMD, DVM, or equivalent and in a faculty position or equivalent.
– Up to $110,000 per year, for up to 1 year.
– The application deadline was Thursday 14 October 2021.
– Funding notification: 31 January 2022.
– Earliest start: 1 March 2022.

Other funding schemes

Industry Discovery & Development Partnerships
– Aimed to promote for-profit interest in JDRF’s mission to find a cure for type 1 diabetes and its complications.
– Biotechnology/ pharmaceutical companies or other for-profit entities, either publicly or privately held.
– JDRF also encourages Partnership applications from companies proposing collaboration with academic researchers.
– Discovery Partnerships: 2 year contract – Up to $250K/yr/2.
– Contact the appropriate Therapeutic Area Program Director.

Conference Grants
– Supports scientific meetings, conferences, and workshops relevant to JDRF mission.
– Does not provide individual support to an applicant for conference attendance.
– Applications are accepted for consideration throughout the year. They should be submitted to the appropriate Scientific Program Staff 3-6 months prior to the meeting date.